Fortune Business Insights values the global psoriasis treatment market share at USD 29.26 billion in 2025. It projects growth to USD 31.51 billion in 2026 and USD 59.89 billion by 2034, a CAGR of 8.36%. North America led in 2025 with a 74.74% share.

Psoriasis is a chronic autoimmune inflammatory disease. Skin cells overproduce, causing red, itchy, painful plaques. Treatment is moving from short-term symptom relief to long-term disease management. Patients and physicians now want clearer skin, fewer flares, and a better quality of life, which supports demand for targeted and convenient therapies.

Growth Drivers

The report ranks five main drivers by their contribution to CAGR:

  • Rising prevalence and a large treated population (2.30%). The National Psoriasis Foundation estimates about 125 million people worldwide, or 2-3% of the global population, have psoriasis. More awareness is also pushing patients into dermatology and rheumatology care.
  • Biologics and interleukin inhibitors (2.05%). These are increasingly used for moderate-to-severe disease.
  • Product innovation (1.85%). The pipeline of oral, topical, and targeted therapies keeps expanding.
  • Demand for long-term control (1.55%). Physicians now aim for near-complete or complete skin clearance.
  • Biosimilars (1.20%). They lower costs and widen access, especially in price-sensitive markets.

Together, these drivers contribute about 9.60% to growth.

Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600

Restraints and Challenges

Restraints subtract roughly 2.44% from growth. The largest is the high cost of biologics and advanced systemic drugs (0.95%). Treatment is long-term, so recurring costs, insurance approvals, formulary rules, and out-of-pocket expenses limit uptake. Reimbursement barriers in price-sensitive markets (0.70%) and treatment switching or variable patient response (0.50%) add further drag.

Unequal access across regions is a related challenge. Developed markets have specialists, specialty pharmacies, and payer support. Many emerging markets rely on topical or conventional drugs and face delayed treatment. The WHO has noted that biologics are valuable but costly, which makes biosimilars important for affordability.

Key Trend

The leading trend is wider use of IL-17 and IL-23 inhibitors. They give durable control, convenient dosing, and a strong chance of reaching PASI 90 or PASI 100 clearance. Companies are expanding labels and building long-term clinical evidence, and new approvals continue to strengthen the class.

Segmentation Highlights

  • Drug class: Interleukin inhibitors lead, helped by ustekinumab biosimilars. TYK2 inhibitors are the fastest growing, with a projected CAGR of 34.96%.
  • Indication: Plaque psoriasis dominates because it is the most common form and has the largest eligible patient pool. Psoriatic arthritis is expected to grow at 11.51%.
  • Product type: Biologics hold the largest share. Non-biologics are projected to grow faster, at 13.79%.
  • Route of administration: Parenteral/systemic therapies dominate because of injectable biologics. Oral therapies are growing faster, at 14.24%.
  • Age group: Adults dominate, while the pediatric segment is projected to grow at 11.14%.
  • Distribution channel: Specialty pharmacies led in 2025 because biologics need specialist prescribing, reimbursement approval, and monitoring. Online pharmacies are the fastest growing, at 16.08%.

Regional Outlook

North America’s market was USD 20.32 billion in 2024 and USD 21.87 billion in 2025. High diagnosis rates, strong dermatology access, and quick adoption of biologics, biosimilars, and oral therapies support its lead.

Europe is the second-fastest growing region, with a projected CAGR of 7.82% and about USD 4.35 billion in 2026. Germany is estimated at roughly USD 1.05 billion and the U.K. at USD 0.64 billion.

Asia Pacific is estimated at USD 2.21 billion in 2026 and is the third-largest region. A large patient pool, better diagnostics, local biologic development, and rising healthcare spending are driving it. 2026 estimates include China at about USD 0.74 billion, Japan at USD 0.61 billion, and India at USD 0.24 billion (about 0.76% of global revenue).

Latin America is estimated at USD 0.81 billion in 2026. The GCC is at USD 0.30 billion and South Africa at about USD 0.07 billion.

Competitive Landscape

The market is moderately consolidated. Profiled companies include AbbVie, Novartis, Johnson & Johnson, Pfizer, Eli Lilly, LEO Pharma, Amgen, UCB, Sun Pharma, Almirall, and Arcutis. Biosimilar-focused players include Teva, Alvotech, Sandoz, Celltrion, and Biocon Biologics.

Recent developments:

  • March 2026: The U.S. FDA approved J&J’s ICOTYDE (icotrokinra), a once-daily oral IL-23 receptor-targeted peptide, for moderate-to-severe plaque psoriasis.
  • March 2026: The FDA approved Bristol Myers Squibb’s Sotyktu (deucravacitinib), a TYK2 inhibitor, for psoriatic arthritis.
  • February 2026: Lilly reported positive Phase 3b results for Taltz combined with Zepbound in patients with psoriasis and obesity.
  • November 2025: Hikma launched a Stelara biosimilar, STARJEMZA, in the U.S.
  • December 2025: Takeda announced positive Phase 3 results for the oral TYK2 inhibitor zasocitinib.

Opportunities

Emerging markets offer the biggest opportunity. Many patients there are undiagnosed or undertreated because of limited dermatology access, low awareness, stigma, and affordability barriers. Awareness campaigns, such as Boehringer Ingelheim’s work with the National Psoriasis Foundation on generalized pustular psoriasis, could bring more patients into treatment.

Conclusion

The report points to strong, innovation-led growth. Oral TYK2 inhibitors and peptides, IL-17/IL-23 biologics, non-steroidal topicals, and biosimilars are reshaping care. High costs and uneven access remain the main constraints. North America will stay the largest market, but Asia Pacific and emerging regions hold the most room for expansion.